CHINA’S JOINT PREVENTION AND CONTROL MECHANISM OF THE STATE COUNCIL announced on Tuesday that China approved clinical trials for 2 sorts of inactivated vaccines for COVID-19. And are effective and safe on macaques and other non-human primates like rats.
The vaccines are developed by the Wuhan Institute of Biological Products of China National Pharmaceutical Group and a Beijing-based unit of Sinovac Biotech. The research team said although it’s still too early to define the simplest animal model for studying COVID-19 infections, the experimental data support the rapid clinical development of COVID-19 vaccines for humans.
According to Yang, the inactivated vaccine has the benefits of advanced research and development technology, mature production processes, controllable quality standards, and good protective effects. it’s the foremost effective path for developing vaccines for a completely unique disease, he added.
“The direction is obvious, the appliance stage is often carried forward as soon because the first two clinical trials get approved. Once the clinical test is successful, vaccines are often produced, and therefore the production capacity can reach quite 100 million yuan a year,” he added.
The research team consists of scientists from laboratories and institutes affiliated with the Chinese Academy of Sciences and health authorities, including the Key Laboratory of Human Disease Comparative Medicine, Key Laboratory of Infection and Immunity, National Laboratory of Macromolecules, National Institute for disease Control and Prevention under Chinese Center for Disease Control and Prevention.
At the company’s lab, he showed us the COVID-19 inactivated vaccine, which took many researchers’ nearly three months to develop. At this lab, researchers are checking what proportion antibody is produced within the blood of animals that are given the vaccine. According to the planet Health Organization, inactivated vaccines are made up of microorganisms (viruses, bacteria, other) that are killed through physical or chemical processes. After immunization, the vaccine antigens cannot replicate within the vaccinated person or cause disease.
Chinese scientists are racing to develop COVID-19 vaccines via five approaches – inactivated vaccines, gene-splicing subunit vaccines, adenovirus vector vaccines, macromolecule vaccines, and vaccines using attenuated influenza virus as vectors. The adenovirus vector vaccine against COVID-19 developed by China’s Academy of Military Medical Sciences has previously been approved and is currently within the second phase of clinical trials.